Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.
about
Alcoholism: A Systems Approach From Molecular Physiology to Addictive BehaviorThe role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical reviewThe neurobiology and genetics of impulse control disorders: relationships to drug addictionsRational development of addiction pharmacotherapies: successes, failures, and prospectsNew developments in the pharmacotherapy of cocaine abuseVarenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.Behavioral architecture of opioid reward and aversion in C57BL/6 substrains.Potent inhibition of alcohol self-administration in alcohol-preferring rats by a κ-opioid receptor antagonistOPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.Covariates of craving in actively drinking alcoholics.Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence.A novel delta opioid receptor antagonist, SoRI-9409, produces a selective and long-lasting decrease in ethanol consumption in heavy-drinking rats.Regulator of G protein signaling 6 is a critical mediator of both reward-related behavioral and pathological responses to alcoholNeurosteroid Binding Sites on the GABA(A) Receptor Complex as Novel Targets for Therapeutics to Reduce Alcohol Abuse and Dependence.Reward processing by the opioid system in the brain.Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats.The opioid receptors as targets for drug abuse medicationThe neural circuitry underlying reinstatement of heroin-seeking behavior in an animal model of relapse.Shared brain vulnerabilities open the way for nonsubstance addictions: carving addiction at a new joint?Long-acting injectable naltrexone for the treatment of alcohol dependence.Genetic factors influencing alcohol dependenceGender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependenceEffects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trialPharmacogenetic treatments for drug addiction: alcohol and opiates.Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mRGS6 as a Novel Therapeutic Target in CNS Diseases and Cancer.Pharmacogenetics of alcohol, nicotine and drug addiction treatments.Binding mode analyses of NAP derivatives as mu opioid receptor selective ligands through docking studies and molecular dynamics simulation.Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.Medications for substance use disorders (SUD): emerging approaches.Direct-to-consumer genetic testing for addiction susceptibility: a premature commercialisation of doubtful validity and value.The potential of pharmacogenomics to treat drug addiction.
P2860
Q22241964-C4CD99E4-CBDF-4702-864F-1AF2299444A0Q24616528-D1E660A3-1F6A-473E-949F-11CB7FDC96E3Q24642641-BC79BB0B-2304-45AA-9169-B86099578279Q27025533-C56DE258-20DC-47B5-931A-8D011345D581Q28302782-B4141118-4C9C-42BA-B4B3-5B61F58D87D9Q30502320-F73952B3-F6B5-445E-878B-A07ED14F6C2EQ30614491-80FEC22B-FC70-4C26-8842-187C3BCA711BQ33750830-F5330EFF-3105-48BE-9E63-A0D3FA0588F4Q33921223-718391DA-6800-4DFD-AFF7-B34717360520Q34043568-AF6DD8A2-FDE5-4500-9F37-445B4BB9BA10Q34078217-D23A63FB-F297-4C41-BE0F-46934E8D3ACFQ34342747-E9183F0A-19FA-423D-B2FF-01D04D6EB6F6Q34822245-30D397E3-61B2-4101-8945-48D793D475F8Q35129073-06810732-0AD6-4769-B5B4-0EE610486A65Q35505547-E153773B-D8F4-414E-A27D-F1403A449FBCQ35786247-806B873E-BCEF-4159-A380-9EC74436C782Q35887957-C8FCD8FB-D13B-44B0-B21D-5F5B19A37F9BQ35978068-CBDBACA1-CC3D-4419-8B9B-5E770FA5DDFCQ36453613-7BD11D23-426C-41D5-A34B-6CB58BFBD6A3Q36900876-2B9391EC-03AB-419E-B0DD-9996AF0B787AQ36972683-AFD1A8B5-FD25-440E-949F-E486C747D689Q37117548-5C4F9DE7-EBD1-4D6F-B797-B3CB74F62AFBQ37133906-9A6ED626-C2B5-4519-ABEF-3844949FB867Q37179217-16263EDA-15F0-4533-87DD-1E7D9B4EC8DAQ37201611-35FCF362-F6E1-4814-A44B-DFD276C2C2ACQ37317909-7D1CFC64-5AB2-4430-B023-4506B17E1F0DQ37600399-DDD4AA8F-AF96-4C0E-8A3E-DB98B77EFA96Q37848476-256B34DB-4185-421D-A348-26025B41F1F9Q38743944-C1D79413-4EDA-465D-91A7-C7AFABCB39C9Q46165138-7A06D6B4-842B-43F6-801F-4366D9CDD1C2Q47731975-CA8CE0AA-9345-4EE0-88BB-997DF4EE0FB1Q48454359-622FBCAA-9C17-4387-8528-97243AFAB175Q52295623-DC90FEDD-2EB7-4532-9CFF-A6E053E67F54
P2860
Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.
@ast
Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.
@en
type
label
Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.
@ast
Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.
@en
prefLabel
Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.
@ast
Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.
@en
P2093
P2860
P1433
P1476
Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.
@en
P2093
Charles P O'Brien
David W Oslin
Wade H Berrettini
P2860
P304
P356
10.1111/J.1369-1600.2006.00036.X
P577
2006-09-01T00:00:00Z